From the Departments of 1Epidemiology and 2Health Behavior and Health Education, University of North Carolina at Chapel Hill, Chapel Hill, NC; 3GlaxoSmithKline, Research Triangle Park, NC; and 4Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Received April 22, 2011; revised and accepted June 7, 2011.
Funding/support: K.B.V. was funded by GlaxoSmithKline through an unrestricted educational grant.
Financial disclosure/conflicts of interest: K.B.V., R.D.B., and R.E.W. are employees of GlaxoSmithKline and hold stock options R.F.D., M.L.J.F., and B.N.G. do not have conflicts of interest to disclose.
Address correspondence to: Kristen B. Van Dole, PhD, MSPH, Worldwide Epidemiology, GlaxoSmithKline, 5 Moore Drive, 17.2110, Research Triangle Park, NC 27709-3398. E-mail: [email protected]